- Global Pharma News & Resources

Bayer appoints Sebastian Guth to lead Pharmaceuticals business in the Americas

Bayer appoints Sebastian Guth to lead Pharmaceuticals business in the Americas

PR Newswire

WHIPPANY, N.J., Sept. 27, 2018

WHIPPANY, N.J., Sept. 27, 2018 /PRNewswire/ -- Bayer today announced the appointment of Sebastian Guth as President of Pharmaceuticals, Americas Region, comprising the United States, Canada, Central and Latin America, effective December 1, 2018.

"Sebastian is a highly respected, seasoned leader in the pharmaceutical industry, and I'm thrilled to have him lead Bayer's largest pharmaceutical business worldwide," said Dieter Weinand, member of Bayer's Board of Management and President of Pharmaceuticals. "Sebastian brings significant global experience gained from leadership roles in strategy, marketing, and business development and a proven track record of successful execution at the local level that will be crucial as we continue our growth in the U.S. and across the Americas region."

A member of Bayer's Pharmaceutical Executive Committee, Guth has since October 2015 served as Executive Vice President and Chief Marketing Officer for Bayer's global Pharmaceuticals business. Previously, he served as Chief Marketing Officer for Bayer's global General Medicine business. Prior to that, he was President & Chief Executive Officer of Bayer Yakuhin Ltd., Osaka, leading Bayer's healthcare business in Japan.

Guth started his career in the pharmaceuticals industry with Schering AG, where he held senior roles in Asia and the Middle East. Guth was later appointed Head of Strategy and Business Development for Schering's European business. Following Bayer's acquisition of Schering in 2006, he acted as Chief Executive Officer of Bayer Turk, Istanbul, and was Senior Representative of the Bayer Group in Turkey.

Guth succeeds Carsten Brunn and will be based in Whippany, New Jersey.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to

Our online press service is just a click away:
Follow us on Facebook:
Follow us on Twitter:

Contact :

Steven Immergut
Bayer U.S.
Mobile: 202-805-9642

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

View original content to download multimedia:


Editor Details

  • Company:
    • PR Newswire
  • Website:
Last Updated: 27-Sep-2018